Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Kamiya Mehla

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5875-1868; OpenAlex author ID A5060280196; NIH RePORTER profile ID 12072158. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 5)
Trials
0
Grants
2
Labs led
2
Collaborators
69
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 3 papers · 2022: none · 2023: none · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers, 2 grants

Papers 23

  1. KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1984↗
  2. Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. Last author DOI 10.1186/s12943-025-02340-8↗
  3. Tumor-stromal metabolic crosstalk in pancreatic cancer. Co-author DOI 10.1016/j.tcb.2025.04.007↗
  4. Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individu… Co-author DOI 10.1016/j.canlet.2024.217321↗
  5. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Co-author DOI 10.1038/s41556-024-01372-4↗
  6. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 … Co-author DOI 10.1038/s41556-024-01417-8↗
  7. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Co-author DOI 10.1073/pnas.2315509121↗
  8. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Co-author DOI 10.1053/j.gastro.2021.06.045↗
  9. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-21-0368↗
  10. Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13092264↗
  11. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. Last author DOI 10.1016/j.bbcan.2020.188387↗
  12. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Last author DOI 10.1016/j.canlet.2020.04.017↗
  13. Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-2926↗
  14. Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-019-0794-6↗
  15. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. Co-author DOI 10.1124/jpet.118.255372↗
  16. Evaluation of Macrophage Polarization in Pancreatic Cancer Microenvironment Under Hypoxia. First author DOI 10.1007/978-1-4939-7665-2_23↗
  17. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  18. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Co-author DOI 10.18632/oncotarget.5843↗
  19. Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. First author DOI 10.1021/bi401329a↗
  20. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Co-author DOI 10.1186/2049-3002-2-18↗
  21. MicroRNAs in pancreatic cancer metabolism. Last author DOI 10.1038/nrgastro.2012.63↗
  22. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Co-author DOI 10.1073/pnas.1203339109↗
  23. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0032996↗

Grants 2

  1. Vitamin B6 Modulates NK Cell Metabolism in Pancreatic Cancer R37CA276924↗
  2. High-fat diet regulates granulocyte metabolism and function in pancreatic cancer U01CA296929↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pankaj Kumar Singh · 18 shared papers, 2012–2026 · strength 2.13
  2. Michael Anthony Hollingsworth · 14 shared papers, 2012–2026 · strength 1.64
  3. Ravi Kumar Thakur · 7 shared papers, 2021–2026 · strength 1.36
  4. Surendra Kumar Shukla · 11 shared papers, 2014–2026 · strength 1.32
  5. Kuldeep Singh Attri · 7 shared papers, 2017–2024 · strength 0.83
  6. Tuo Hu · 5 shared papers, 2021–2026 · strength 0.81
  7. Chunbo He · 5 shared papers, 2021–2026 · strength 0.81
  8. Ryan J. King · 7 shared papers, 2015–2026 · strength 0.78
  9. Nina V. Chaika · 10 shared papers, 2012–2024 · strength 0.77
  10. Paul M. Grandgenett · 6 shared papers, 2017–2024 · strength 0.71
  11. Divya Murthy · 5 shared papers, 2017–2024 · strength 0.59
  12. Sai Sundeep Kollala · 3 shared papers, 2024–2026 · strength 0.50
  13. Susanna Varkey Ulahannan · 3 shared papers, 2024–2026 · strength 0.50
  14. Aneesha Dasgupta · 5 shared papers, 2015–2024 · strength 0.47
  15. Nicholas James Mullen · 2 shared papers, 2021–2025 · strength 0.45
  16. Robert Powers · 6 shared papers, 2012–2024 · strength 0.43
  17. Spas Dimitrov Markov · 3 shared papers, 2020–2026 · strength 0.42
  18. Voddu Suresh · 2 shared papers, 2024–2026 · strength 0.41
  19. Teklab Gebregiworgis · 5 shared papers, 2012–2024 · strength 0.38
  20. Scott E. Mulder · 3 shared papers, 2021–2024 · strength 0.36
  21. Clara S. Mundry · 2 shared papers, 2020–2024 · strength 0.33
  22. Joshua J. Souchek · 3 shared papers, 2015–2024 · strength 0.32
  23. Enza Vernucci · 4 shared papers, 2015–2021 · strength 0.28
  24. Rosa F. Hwang · 2 shared papers, 2024 · strength 0.28
  25. Ajay Jain · 2 shared papers, 2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.